Browse studies, page 103
Page 103 of 1,286, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Relationship Between the First Undisturbed Sleep Period and Diuretic and Urine Storage States of the First Void After Sleep Neurourology and Urodynamics, 2025
- Modern Management of Neurogenic Bladder Current Treatment Options in Pediatrics, 2026
- What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine Advances in Therapy, 2022
- Mirabegron for overactive bladder Canadian Family Physician, 2026
- Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease Parkinsonism & Related Disorders, 2023
- Treatment modalities for paediatric functional daytime lower urinary tract disorders: an updated review Therapeutic Advances in Urology, 2024
- Optimizing Mirabegron Stability in Human Plasma: Method Development, Validation Through Integration of Esterase Inhibitors and Stabilizers Biomedical Chromatography, 2025
- Shifting the treatment paradigm in idiopathic overactive bladder International Journal of Clinical Practice, 2020
- Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis Frontiers in Medicine, 2022
- Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions Clinical Drug Investigation, 2021
- Management of mixed urinary incontinence: IUGA committee opinion International Urogynecology Journal, 2024
- The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review BMC Women s Health, 2024
- Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes Toxins, 2023
- Hyperactive Bladder in Men: Modern Recommendations and Practical Approaches to Diagnosis and Treatment Health of Man, 2023
- Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies LUTS Lower Urinary Tract Symptoms, 2019
- Treatment of urge incontinence in postmenopausal women: A systematic review Archivio Italiano di Urologia e Andrologia, 2023
- Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study Medicina, 2024
- Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives International Journal of Women s Health, 2023
- Non-Surgical Management of Urinary Incontinence The Journal of the American Board of Family Medicine, 2024
- Results of a study examining the use of onabotulinumtoxinA in pediatric patients with overactive bladder Journal of Pediatric Urology, 2024
- Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis Toxins, 2025
- Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective Journal of Comparative Effectiveness Research, 2023
- Sex Differences in Prescribing Patterns of Anticholinergics and β3‐Adrenoceptor Agonists for Overactive Bladder: A Nationwide Study in Japan, FY2017 – FY2024 LUTS Lower Urinary Tract Symptoms, 2026
- Drug-drug interactions of drugs for treatment of overactive bladder Klinická farmakologie a farmacie, 2025
- Optimizing Nonsurgical Treatments of Overactive Bladder in the United States Urology, 2020
- Review of the Impact and Burden of Urinary Urgency on Adults with Overactive Bladder International Journal of Clinical Practice, 2024
- Concomitant Overactive Bladder Treatment and Adherence to Pelvic Floor Physical Therapy International Urogynecology Journal, 2025
- Upcoming New Drug Therapies for Nocturia - A Nonsystematic Stepwise Review Annals of Reviews & Research, 2021
- Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition) International Journal of Urology, 2021
- Higher skin sympathetic nerve activity as a potential predictor of overactive bladder in females refractory to oral monotherapy The Kaohsiung Journal of Medical Sciences, 2024
- Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient Clinical Interventions in Aging, 2020
- β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy Neurourology and Urodynamics, 2025
- Medicamenteuze behandeling van de overactieve blaas: het heden en de toekomst Tijdschrift voor Urologie, 2021
- Analysis of Urinary Retention Caused by Selective β 3-adrenoceptor Agonists Using the Japanese Adverse Drug Event Report Database (JADER) Die Pharmazie, 2023
- Off-Target Effects of Mirabegron on Muscarinic Receptors Future Pharmacology, 2026
- Comparative assessment of oral medications for overactive bladder in older adults: a systematic review and network meta-analysis The Aging Male, 2025
- Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. Letter The Journal of Urology, 2023
- USE of anticolinergic drugs for the therapy of patients with overactive bladder according to the guidelines of the european association of urology 2025 Ukrainian Journal of Urology, 2025
- Side effects of medical therapy for non-neurogenic lower urinary tract symptoms in children: a UK-based single centre retrospective case-note review BMJ Paediatrics Open, 2026
- Effects of Treatment and Weather Variables on Nocturnal Enuresis: Long-Term Analysis Using the Classification and Regression Trees Model Cureus, 2025
- ไวบกรอน: ยาตวใหมสำหรบรกษาภาวะกระเพาะปสสาวะบบตวไวเกน Thai Journal of Hospital Pharmacy, 2026
- Recent advances in managing overactive bladder F1000Research, 2020
- Current pharmacotherapy of overactive bladder International braz j urol, 2021
- Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products Scientific Reports, 2026
- Expert perspectives on the effectiveness and combination strategies of mirabegron in the management of overactive bladder International Journal of Urology Sciences, 2026
- Trends in Overactive Bladder Prescriptions from 2020 to 2022 Gynecology & Reproductive Health, 2026
- Sex‐ and Age‐Specific Trends in Prescriptions of Beta‐3 Agonists and Anticholinergics in Japan: A Nationwide Prescription Database Study LUTS Lower Urinary Tract Symptoms, 2026
- Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns Neurourology and Urodynamics, 2024
- Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults Cochrane Database of Systematic Reviews, 2023
- Navigating the challenges of overactive bladder management in women World Journal of Urology, 2026
- Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. Reply The Journal of Urology, 2023
- Treating and Managing Urinary Incontinence: Evolving and Potential Multicomponent Medical and Lifestyle Interventions Research and Reports in Urology, 2023
- Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial ( ADVISR ) protocol BMJ Open, 2025
- Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review Advances in Therapy, 2023
- Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis European Urology Focus, 2021
- Efficacy of novel β 3 ‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study International Journal of Urology, 2018
- Clinical Study on the Treatment of Pediatric Primary Nocturnal Enuresis by Integrated Traditional Chinese and Western Medicine Indian Journal of Pharmaceutical Sciences, 2022
- A Novel Spectrofluorimetric Method for Vibegron in the Newly FDA Approved Pharmaceutical Formulation and in Human Plasma: Analytical QbD Strategy for Method Development and Optimization Journal of Fluorescence, 2024
- Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations Research and Reports in Urology, 2022
- Comparison of solifenacin versus mirabegron in women with overactive bladder presenting at a tertiary care hospital Insights-Journal of Health and Rehabilitation, 2025
- Comparison of efficacy and safety of mirabegron and vibegron in the treatment of Overactive Bladder (OAB) in older women: A systematic review and meta-analysis PLoS ONE, 2025
- Long‐term safety and efficacy of the novel β 3 ‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study International Journal of Urology, 2018
- Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA PharmacoEconomics, 2022
- Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T‐cell leukemia virus type I‐associated myelopathy/tropical spastic paraparesis IJU Case Reports, 2024
- Comparative Assessment of Efficacy and Safety of approved Oral Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis Research Square, 2023
- Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial ( VAPOR TRIAL ) LUTS Lower Urinary Tract Symptoms, 2024
- Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial LUTS Lower Urinary Tract Symptoms, 2023
- Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis Advances in Therapy, 2024
- Long-term efficacy and safety of solifenacin, mirabegron, and their combination for overactive bladder: a systematic review Frontiers in Pharmacology, 2026
- Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis European Journal of Obstetrics & Gynecology and Reproductive Biology, 2026
- Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross‐Trial Synthesis of Benefit Probabilities and Decision Thresholds LUTS Lower Urinary Tract Symptoms, 2026
- Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues Naunyn-Schmiedeberg s Archives of Pharmacology, 2025
- Initial experience with vibegron for the treatment of neurogenic lower urinary tract storage dysfunction in patients with spinal cord injury Continence, 2022
- Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder BMC Urology, 2023
- Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison Advances in Therapy, 2021
- An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder Therapeutics and Clinical Risk Management, 2022
- A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome International Urology and Nephrology, 2014
- The comparison of outcomes of solifanacin plus behavioral therapy versus Mirabegron alone in management of overactive bladder Journal of University Medical & Dental College, 2025
- Antimuscarinics for burn patients: Helpful or harmful for sensation recovery? Burns, 2025
- Exploring the therapeutic potential of Beta-3 adrenergic agonists in overactive bladder: A comparative analysis of monotherapy versus combination therapy strategies Wiadomosci lekarskie, 2026
- Urine Epidermal Growth Factor/Creatinine Ratio in Female Patients with Overactive Bladder and Recurrent Lower Urinary Tract Infection Gynecology and Minimally Invasive Therapy, 2026
- A Comparison of U.S. Individual and Family Plan Medication Coverage for Overactive Bladder Urogynecology, 2024
- Trends in Medicare Coverage of Overactive Bladder Medications in the United States Urogynecology, 2024
- The efficacy and safety of solifenacin in patients with overactive bladder syndrome Collegium Antropologicum, 2012
- Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study International Urology and Nephrology, 2014
- Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice International Neurourology Journal, 2014
- Comparison of Behaviour Therapy versus Combination Therapy, Solifenacine with Behaviour Therapy in the Management of the Nocturnal Enuresis Annals of Punjab Medical College, 2026
- Re: Influence of the Short-Term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women with Urinary Incontinence Journal of Urology, 2019
- Evaluation of in Vitro and in Vivo Transdermal Absorption of Solifenacin Succinate Chemical and pharmaceutical bulletin, 2019
- Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and β3-adrenoceptor agonists Scientific Reports, 2025
- Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice 2016
- Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms Arab Journal of Urology, 2016
- Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study International Neurourology Journal, 2018
- PD14-01 ONCE-DAILY VIBEGRON, A NOVEL ORAL &bgr;3 AGONIST DOES NOT INHIBIT CYP2D6, A COMMON PATHWAY FOR DRUG METABOLISM IN PATIENTS ON OAB MEDICATIONS Journal of Urology, 2019
- Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence BMC Urology, 2023
- RE: Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder Neurourology and Urodynamics, 2019
- Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database Urology, 2017
- Comparison of the Effects of Solifenacin Succinate for the Treatment of Overactive Bladder with Extended Release Tolterodine 2020
- Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) European Urology, 2018
- Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected]. Journal of Urology, 2016
